Arbor Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Arbor Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Arbor Pharmaceuticals: 14 sponsored US clinical trials, none currently recruiting.
Arbor Pharmaceuticals sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 7 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Otitis Media, with 1 trials.
Top-decile sponsor footprint
Arbor Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
NCT06247488
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
NCT06097676
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
NCT03659929
Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
NCT02684838
Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets
NCT02522208
An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
NCT02235909
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)
NCT02049164
Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting
NCT01986062
Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media
NCT02044341
Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)
NCT02074007
Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09
NCT02027155
AR08 for Treatment of ADHD in Children
NCT01876719
Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis Media
NCT01588535
A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers
NCT01587313
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 4 |
| Phase 4 | 3 |
Therapeutic Areas
How the Arbor Pharmaceuticals archive is shaped
14 indexed studies, none listed as recruiting (0% open); 11 completed (79%).
Phase mix: 7 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Otitis Media (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Arbor Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Arbor Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Arbor Pharmaceuticals page
14 registered trials is a research-attention snapshot, not an endorsement of Arbor Pharmaceuticals or any single study.
- None of Arbor Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Otitis Media is the condition Arbor Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Otitis Media trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Arbor Pharmaceuticals pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.